Series - Scientific Developments

BIO, CSBA, and AdvaMed hosted a special briefing to discuss the success of SBIR/STTR programs, their economic impact, and the important next steps to Federal reauthorization.

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are highly competitive award-based programs that encourage domestic small businesses to engage in Federal Research/Research and Development with the potential for commercialization.

Federal funding for the SBIR/STTR Program will expire on September 30, 2022, and we need your support to ensure timely reauthorization! Hear from successful SBIR/STTR grantees and technical experts on these vital programs. After this webinar, you will be able to effectively advocate for Federal SBIR/STTR program reauthorization.

• https://action.bio.org/X8gCA7U
• https://www.advamed.org/takeaction/?vvsrc=%2fcampaigns%2f96142%2frespond%3futm

• Opening Remarks: Overview and Department of Defense Priorities
• Investing at the Speed of Need: Novel Technologies and Platforms to Accelerate Drug Development

The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This BIO-hosted webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense.

The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.

• Repurposing and Redirecting: An Alternate Approach to Accelerating Medical Countermeasures

The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This BIO-hosted webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense.

The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.

How to Work with the Department of Defense

The US Government invests in biomedical research in many ways, including direct funding of some critical R&D areas for diagnostics, vaccines, and therapeutics that could strengthen biodefense preparedness. This BIO-hosted webinar details for the biotechnology corporate and academic community the many new and previously available sources of capital, as well as the processes for applying for funding, from the US Department of Defense.

The Department of Defense (DoD) is continuously engaging in efforts to protect the warfighter from a broad array of threats. Preparing for and responding to these threats requires key partnerships with the industry to develop vaccines, therapeutics, and diagnostics that are designed specifically to meet the unique needs of the warfighter in various situations. Many of the investments made through these partnerships also support broader applications of key biotechnologies for other unmet healthcare needs. This important webinar represents an opportunity for BIO members and the whole biotechnology community to get an update about the priorities and programs within the DoD and the ways companies can work with the Agency on their priorities.

The Biotechnology Innovation Organization (BIO) presents this webinar to hear from top Big Pharma professionals in search & evaluation licensing and venture investing about what it takes to get them interested in a new technology. We look at their recent deals and ask why they got done, explore the challenges and learn what makes a technology exciting. Then we dive into a discussion on what tech/modalities and platforms are seen as exciting. Finally, we get advice for those biotechs that are ready for licensing or investment.

The Biotechnology Innovation Organization (BIO) hosts this candid chat with three major investors from our biotechnology community. Gain valuable insights and be ready to ace pitching world-changing solutions in the face of a down-trending market at the 2022 BIO International Convention, June 13-16, in San Diego, California.

For more details visit http://bio.org/convention

Introduction from Mike Liccardo, VP Corporate Development and CFO, ShareVault

Biotech Intellectual Property Law in Focus: Webinar Series

Navigating Parallel BPCIA and PTAB Proceedings – Recent Developments and Strategic Considerations

This panel hosted by the Biotechnology Innovation Organization (BIO) discusses relevant case law and trends in BPCIA litigation and related PTAB proceedings, followed by a “roundtable” on the factors that may influence litigation strategy, early case resolution, and market entry.

A private biotech that announces a definitive agreement with a SPAC jumps into the public investor spotlight and faces that attention with fewer guardrails than the IPO process, plus a need to transform board, investor, and regulatory relations. Given that most SPAC merger deals also involve follow-on PIPE investment rounds or other transactions, the full fundraising benefits of the deal strategy require a smooth de-SPAC process that a private biotech would never have encountered before. View this webinar to learn best practices for navigating from SPAC deal announcement through de-SPAC process to regular life managing a publicly traded company.  

Innovation flourishes when science and consumer values are aligned and complement one another. Regulatory approaches towards innovative products cannot exist in isolation. They should be supported by credible transparency measures. A proactive approach to transparency stands to build trust and foster an inclusive environment to address our most pressing societal, nutritional, and environmental concerns. This webinar will explore the meaningful – and sometimes unexpected- actions and partnerships that are growing trust in the innovation ecosystem and delivering access to innovations that benefit people and the planet.